#USA #Stuart Therapeutics #Tracy Valorie #Jason Werner #Stuart, Florida

Stuart Therapeutics Welcomes Two New Board Members

Stuart Therapeutics is proud to announce the addition of two distinguished leaders, Tracy Valorie and Jason Werner, to its Board of Directors. This strategic move marks an important phase for the company, enhancing its leadership and expanding its expertise in ophthalmology therapeutics.

A New Direction in Leadership

With the passing of Robert O. Baratta, MD, and the recent resignation of retired US Representative Diane Black, the board has now expanded to five members with the inclusion of Valorie and Werner. Eric Schlumpf, the President and CEO of Stuart, expressed enthusiasm about these appointments, stating that their extensive industry experience will play a crucial role as the company advances its developmental and commercialization efforts in ocular therapies.

Tracy Valorie's Extensive Background

Tracy Valorie brings over three decades of experience in the pharmaceutical and biotech sectors to the table. As the owner of TMV Associates LLC since July 2019, she has built a reputation as a strategic business consultant. Her previous roles include serving as the senior vice president and general manager of U.S. pharmaceutical and surgical sectors at Bausch + Lomb until May 2019. At Pfizer Inc., she was responsible for the commercial development of global ophthalmology brands, showcasing her deep expertise in the field. Valorie holds both a Master of Business Administration from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the University of Connecticut. Her recent contributions to the Glaucoma Research Foundation highlight her ongoing commitment to advancing ocular health.

Jason Werner's Notable Experience

Adding to the board's prowess, Jason Werner currently serves as Executive Chairman of Sightstream Biotherapeutics, a biotech firm dedicated to developing regenerative therapies for ocular conditions. His previous leadership roles include being the co-founder and Chief Operating Officer of Eyevance Pharmaceuticals, guiding the company through its acquisition by Santen Pharmaceuticals. Werner has also held various positions in commercial development and corporate strategy at well-known companies such as Sun Pharma and Inspire Pharmaceuticals, all within the ophthalmic landscape. He earned a Bachelor of Science in Business Administration from the University of New Hampshire.

Preparing for Future Growth

The addition of Valorie and Werner comes at a pivotal time for Stuart Therapeutics, which is gearing up for key development milestones and an expanding pipeline. With the progression of its lead therapeutic asset, ST-100, into the final stages of its Phase 3 clinical trial—results of which are anticipated in the first quarter of 2025—the company is poised to make meaningful advancements in treating underserved ophthalmic disorders.

Stuart Therapeutics is also actively developing innovative programs targeting retinal diseases and myopia, alongside a partnership focusing on neuroprotection in glaucoma with Glaukos Corp. This collaborative approach places the company at the forefront of the ophthalmic therapeutics market.

Looking Ahead

Both new board members expressed excitement about their roles within Stuart Therapeutics. Tracy Valorie noted her eagerness to contribute to a biotech firm focused on developing groundbreaking treatments. Meanwhile, Jason Werner emphasized the significant opportunities ahead and the importance of maximizing shareholder value while ensuring that novel therapeutics reach the patients in need.

As Stuart Therapeutics enters this new chapter, the leadership team looks forward to leveraging the skills and experiences of Valorie and Werner to enhance the company's influence in the ophthalmic sector. The journey forward looks promising with fresh ideas aimed at revolutionizing patient care in this critical therapeutic area.